Inozyme Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Inozyme Pharma has a total shareholder equity of $94.4M and total debt of $45.3M, which brings its debt-to-equity ratio to 48%. Its total assets and total liabilities are $155.7M and $61.3M respectively.
Key information
48.0%
Debt to equity ratio
US$45.33m
Debt
| Interest coverage ratio | n/a |
| Cash | US$144.52m |
| Equity | US$94.42m |
| Total liabilities | US$61.29m |
| Total assets | US$155.71m |
Recent financial health updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Financial Position Analysis
Short Term Liabilities: INZY's short term assets ($153.0M) exceed its short term liabilities ($15.5M).
Long Term Liabilities: INZY's short term assets ($153.0M) exceed its long term liabilities ($45.8M).
Debt to Equity History and Analysis
Debt Level: INZY has more cash than its total debt.
Reducing Debt: INZY's debt to equity ratio has increased from 0% to 48% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INZY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INZY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27% each year